A solid tumor is an abnormal tissue mass that usually originates from an organ. Solid tumors are either benign (non-cancerous) or malignant (cancerous). Different types of solid tumors are named based on the cell type that they originate from (1). Examples of solid tumors are carcinomas, adenocarcinomas and sarcomas, and the most diagnosed cancers are lung, breast, prostate, and colorectal cancer (2).

With increased complexity in solid tumor protocol design, endpoints, emerging biomarkers, and time sensitivity due to end-of-life clinical trial patients (3), Cerba Research provides an adaptive oncology team with access to the latest science and technology and offers a wide range of integrated specialty and safety testing for solid tumor clinical trials. Get in touch to learn more.

CD3 Expression In Colorectal Cancer: We Deliver Reliable, Reproducible Results

Solid tumor research and development often face significant challenges, and complex clinical trials require a laboratory partner who provides services throughout the development spectrum. Cerba Research understands the complexities of cancer research, its associated treatment guidelines (4), and biomarkers used for various study endpoints. Cerba Research offers a wide range of services that can specifically support solid tumor research in this new era of precision medicine. We also offer end-to-end oncology solutions from discovery to post-market authorization for your global / regional trials.

In the past 5 years, Cerba Research performed many early-phase solid tumor projects. Most of our first-in-human (FIH) studies include dose escalation / expansion studies with patient populations suffering from advanced or metastatic solid tumors. Cerba Research also has experience with breast cancer, prostate cancer, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC), among other solid indications. Notably, the laboratory has played a pivotal role in the approval of innovative drugs for indications like breast cancer, NSCLC, and high-risk neuroblastoma.

Our team is experienced in many innovative techniques. We have a global network of laboratories that offers a wide range of capabilities, ranging from safety testing (also known as routine testing) to NGS broad-panel assays, ctDNA panels, immunohistochemistry (IHC), flow cytometry (FCM), immunoassays, immunogenicity, qPCR, ddPCR, NanoString®, and more. We also facilitate state-of-the-art technologies, subject matter expertise, specialized logistics, and operations to accelerate your oncology research and development. Interested in artificial intelligence (AI) image analysis for your lung cancer trial? Check out our resources here.

Remember that if we don’t have it, we can customize it. Thanks to our expertise in assay development, validation (5), and customization capabilities, we have garnered ~16,000 patients screened and 12,710+ randomized within our solid tumor programs since 2018.

Cerba OncoSign FFPE panel covers mutations with established and emerging values across the lung, ovarian, breast, colon, melanoma, bladder, brain, and more. This comprehensive tumor genomic profiling assay evaluates 50 genes, including 17 fusions, for multiple variant types. It is also performed on FFPE for routine practice in parallel with HRD status, which is CE-IVD marked. It is performed on FFPE with 2 tubes containing 5 curls of 5 u thickness (1 for DNA & 1 for RNA).

The gene list: AKT1, ALK, AR, ATRX, BAP1, BRAF, BRCA1/2, CDK4/6, CDKN2A, CTNNB1, EGFR, EIF1AX, ERBB2/3, ESR1, FGFR1/2/3, FOXL2, GNA11, GNAQ, GNAS, H3C2/3, H3F3A/B, HRAS, IDH1/2, KEAP1, KIT, KRAS, MAP2K1, MET, MYD88, NRAS, PDGFRA, PIK3CA, POLD1, POLE, PTEN, RAF1, RB1, RET, SF3B1, STK11, TERT, TP53.

Cerba Research: OncoSign FFPE (50 Genes)

Cerba OncoSign ctDNA panel covers mutations with established and emerging values across the lung, ovarian, breast, colon, melanoma, bladder, and more. This comprehensive tumor genomic profiling assay evaluates 50 genes for multiple variant types for the detection of AKT1, ALK, AR, ATRX, BAP1, BRAF, BRCA1/2, CDK4/6, CDKN2A, CTNNB1, EGFR, EIF1AX, ERBB2/3, ESR1, FGFR1/2/3, FOXL2, GNA11, GNAQ, GNAS, H3C2/3, H3F3A/B, HRAS, IDH1/2, KEAP1, KIT, KRAS, MAP2K1, MET, MYD88, NRAS, PDGFRA, PIK3CA, POLD1, POLE, PTEN, RAF1, RB1, RET, SF3B1, STK11, TERT, TP53. It is performed on liquid biopsies with 2 tubes of 8,5 ml (Streck Cell-Free DNA BCT®).

Our clients are supported from pre-clinical to post-market authorization with our in-depth biologics and biosimilars experience. We offer long-standing scientific expertise in pharmacokinetics (PK) and immunogenicity (antibody-drug antibodies (ADAs) and neutralizing antibodies (NAbs)) with a standardized or a customized approach as per your vision.

Did you know that Cerba Research Canada was instrumental in the PK and immunogenicity validation and implementation of bevacizumab? A mAb is approved globally for various solid tumors, such as metastatic colorectal cancer, advanced or metastatic non-small cell lung cancer, and recurrent glioblastoma, among other tumor types (6).

Our focus extends from mAbs to CGTs, ADCs, and more. In addition, we are Good Laboratory Practice (GLP), the College of American Pathologists (CAP), and Clinical Laboratory Improvement Amendments (CLIA) accredited for your regulatory requirements.